Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)

Ruth Nabisere, Joseph Musaazi, Paolo Denti, Florence Aber, Mohammed Lamorde, Kelly E Dooley, Rob Aarnoutse, Derek J Sloan, Christine Sekaggya-Wiltshire, Ruth Nabisere, Joseph Musaazi, Paolo Denti, Florence Aber, Mohammed Lamorde, Kelly E Dooley, Rob Aarnoutse, Derek J Sloan, Christine Sekaggya-Wiltshire

Abstract

Background: Tuberculosis (TB) is a significant public health problem that causes substantial morbidity and mortality. Current first-line anti-TB chemotherapy, although very effective, has limitations including long-treatment duration with a possibility of non-adherence, drug interactions, and toxicities. Dose escalation of rifampicin, an important drug within the regimen, has been proposed as a potential route to higher treatment efficacy with shorter duration and some studies have suggested that dose escalation is safe; however, these have almost entirely been conducted among human immunodeficiency (HIV)-negative TB patients. TB-HIV co-infected patients on antiretroviral therapy (ART) are at increased risk of drug-drug interactions and drug-related toxicities. This study aims to determine the safety of higher doses of rifampicin and its effect on the pharmacokinetics of efavirenz (EFV) and dolutegravir (DTG) in TB-HIV co-infected patients.

Methods: This study is a randomized, open-label, phase IIb clinical trial among TB-HIV infected adult outpatients attending an HIV clinic in Kampala, Uganda. Patients newly diagnosed with TB will be randomized to either standard-dose or high-dose rifampicin (35 mg/kg) alongside standard TB treatment. ART-naïve patients will be randomly assigned to first-line ART regimens (DTG or EFV). Those who are already on ART (DTG or EFV) at enrollment will be continued on the same ART regimen but with dose adjustment of DTG to twice daily dosing. Participants will be followed every 2 weeks with assessment for toxicities at each visit and measurement of drug concentrations at week 6. At the end of intensive-phase therapy (8 weeks), all participants will be initiated on continuation-phase treatment using standard-dose rifampicin and isoniazid.

Discussion: This study should avail us with evidence about the effect of higher doses of rifampicin on the pharmacokinetics of EFV and DTG among TB-HIV co-infected patients. The trial should also help us to understand safety concerns of high-dose rifampicin among this vulnerable cohort.

Trial registration: ClinicalTrials.gov, ID: NCT03982277. Registered retrospectively on 11 June 2019.

Keywords: Antiretrovirals; HIV; Pharmacokinetics; Rifamycins; Tuberculosis.

Conflict of interest statement

None of the authors have any competing interests to declare.

Figures

Fig. 1
Fig. 1
Diagram showing the randomization process
Fig. 2
Fig. 2
Schedule of enrollment, interventions, and assessments
Fig. 3
Fig. 3
Study schema

References

    1. World Health Organization (WHO) Global tuberculosis report 2018. Geneva: World Health Organization; 2018.
    1. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007;51(8):2994–2996. doi: 10.1128/AAC.01474-06.
    1. Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, et al. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. J Antimicrob Chemother. 2017;72:1172–1177.
    1. Chang KC, Leung CC, Yew WW, Kam KM, Yip CW, Ma CH, et al. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur J Clin Microbiol Infect Dis. 2008;27(6):467–472. doi: 10.1007/s10096-007-0454-6.
    1. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009;48(12):1685–1694. doi: 10.1086/599040.
    1. Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39–49. doi: 10.1016/S1473-3099(16)30274-2.
    1. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191(9):1058–1065. doi: 10.1164/rccm.201407-1264OC.
    1. Peloquin CA, Velasquez GE, Lecca L, Calderon RI, Coit J, Milstein M, et al. Pharmacokinetic evidence from the HIRIF trial to support increased doses of rifampin for tuberculosis. Antimicrob Agents Chemother. 2017;61(8).
    1. Schutz C, Ismail Z, Proxenos CJ, Marais S, Burton R, Kenyon C, et al. Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. S Afr Med J. 2012;102:506–511. doi: 10.7196/SAMJ.5650.
    1. Satyaraddi A, Velpandian T, Sharma SK, Vishnubhatla S, Sharma A, Sirohiwal A, et al. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tuberc Lung Dis. 2014;18(2):188–195. doi: 10.5588/ijtld.13.0128.
    1. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet. 2003;42(9):819–850. doi: 10.2165/00003088-200342090-00003.
    1. Court MH, Almutairi FE, Greenblatt DJ, Hazarika S, Sheng H, Klein K, et al. Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6. Antimicrob Agents Chemother. 2014;58(7):4145–4152. doi: 10.1128/AAC.02532-14.
    1. Kwara A, Yang H, Antwi S, Enimil A, Gillani FS, Dompreh A, et al. Effect of rifampin-isoniazid-containing antituberculosis therapy on efavirenz pharmacokinetics in HIV-infected children 3 to 14 years old. Antimicrob Agents Chemother. 2019;63(1):e01657–e01618.
    1. CDC . Managing drug interactions in the treatment of HIV-related tuberculosis. 2014.
    1. Dooley KE. Twice-daily dolutegravir is safe and effective when used alongside TB treatment. Boston: Conference on Retroviruses and Opportunistic Infections; 2018.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe